Neurocrine's $50M bet on Idorsia drug flames out in second PhII
The drug that Neurocrine Biosciences licensed from Idorsia for $50 million has flunked a second Phase II study, failing to help pediatric patients with a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
